Atritech, Inc. (Atritech) is a clinical stage medical device company engaged in the development, manufacture and sales of medical products for cardiovascular markets. The company focuses on the development of minimally invasive technologies specifically designed for the prevention of atrial fibrillation related stroke. Its flagship product, the WATCHMAN left atrial appendage system is used for the treatment of patients suffering from atrial fibrillation. This system is permanently implanted through a catheter inside the left atrial appendage of the heart. The products offered by the company are certified with CE mark and approved by FDA. Atritech is headquartered in Minnesota, the US.
In January 2011, Boston Scientific Corporation entered into a definitive merger agreement with Atritech, under which Boston Scientific Corporation will acquire Atritech.